Last reviewed · How we verify

Inactivated, split-virion influenza virus

Sanofi Pasteur, a Sanofi Company · Phase 2 active Biologic

Stimulates an immune response against influenza virus

Stimulates an immune response against influenza virus Used for Influenza prevention.

At a glance

Generic nameInactivated, split-virion influenza virus
Also known asVaxigrip®, Fluzone®
SponsorSanofi Pasteur, a Sanofi Company
Drug classInfluenza vaccine
ModalityBiologic
Therapeutic areaInfectious Disease
PhasePhase 2

Mechanism of action

This inactivated, split-virion influenza virus vaccine works by exposing the body's immune system to a small, harmless piece of the influenza virus, prompting the body to produce antibodies that can fight the flu.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: